Although inhibition of VEGFR- or PDGFR-regulated intracellular kinase pathways in endothelial cells or pericytes is only one of multiple mechanisms of sorafenib action, expression levels of these growth factors or relevant receptors in HCC tissues have been evaluated to predict the clinical outcome of patients receiving sorafenib [34–39]. Here, PDGFRB is linked to hepatocellular carcinoma.